EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways

Wenxiao Xia, Huan Zhang, Libo Liu, Chenchen Tu, Xiantao Song

Theranostics · 17.06.2026 · 16 (13) · 7715-7734

DOI: 10.7150/thno.127500 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Theranostics, erschienen am 17.06.2026. Verfasst von Wenxiao Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myocarditis. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMyocarditisHumansAnimalsT-LymphocytesMacrophagesAutoimmunity

Stichwörter der Autor:innen

cardiac autoimmunityimmune checkpoint inhibitorsmyocarditistargeted therapies

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China.

Zitieren

APA

Xia, W., Zhang, H., Liu, L., Tu, C., & Song, X. (2026). Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways. Theranostics, 16(13), 7715-7734. https://doi.org/10.7150/thno.127500

Vancouver

Xia W, Zhang H, Liu L, Tu C, Song X. Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways. Theranostics. 2026;16(13):7715-7734. doi:10.7150/thno.127500

BibTeX
@article{Xia2026,
  author = {Xia, Wenxiao and Zhang, Huan and Liu, Libo and Tu, Chenchen and Song, Xiantao},
  title = {Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways},
  journal = {Theranostics},
  year = {2026},
  volume = {16},
  number = {13},
  pages = {7715--7734},
  doi = {10.7150/thno.127500}
}
Kostenlos starten →